Early antibodies for HIV-positive infants to improve life (2)
Part of Infections clinical trials.
This trial tests whether giving early neutralizing antibodies can help infants living with HIV control the virus better. It aims to improve their long-term health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is 1 day to 1 year old and has HIV diagnosed by a standard test.
- Your baby weighs more than 2.5 kg (about 5.5 pounds).
- Your baby has received little or no HIV treatment (less than 30 days of triple therapy).
- Your baby is stable enough to be an outpatient, or can start the study at their first clinic visit.
- Your baby has not received any neutralizing antibody therapy before.
- Your baby does not have serious health problems like active tuberculosis, severe malnutrition, or a life-threatening illness.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a special neutralizing antibody (bNAb) early to infants living with HIV can help their immune system fight the virus better. It's for babies under 1 year old who are starting HIV treatment for the first time.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
This trial tests two lab-made antibodies that may help control HIV without daily pills. It is for people who started HIV treatment very early and now take a break from their regular meds under close monitoring.
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
This study tests whether a combination of special antibodies (bNAbs) can help control HIV without daily medication. It involves several steps and is for children who are already doing well on ART.
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.